Pharmaceuticals Australia

Australia Lysosomal Storage Disease Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Lysosomal Storage Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Disease, Treatment, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $171.6 Mn Placeholder estimate
Estimate 2025 $186.0 Mn 1.4% of the global market
Projected 2034 $384.4 Mn 106.7% Adds $198.4 Mn over 9 forecast years
CAGR 2025–2034 8.4% Faster than 37% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.35% of the global market.
  • In APAC, the largest is China at $1.12 Bn.
  • Fastest growing: India at 9.9% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$198.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Lysosomal Storage Disease Treatment Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $171.6 Mn — —
2025 (base) $186.0 Mn +$14.4 Mn —
2026 (forecast) $201.6 Mn +$15.6 Mn +8.4%
2027 (forecast) $218.6 Mn +$16.9 Mn +17.5%
2028 (forecast) $236.9 Mn +$18.4 Mn +27.4%
2029 (forecast) $256.8 Mn +$19.9 Mn +38.1%
2030 (forecast) $278.4 Mn +$21.6 Mn +49.7%
2031 (forecast) $301.8 Mn +$23.4 Mn +62.2%
2032 (forecast) $327.1 Mn +$25.4 Mn +75.9%
2033 (forecast) $354.6 Mn +$27.5 Mn +90.6%
2034 (forecast) $384.4 Mn +$29.8 Mn +106.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Lysosomal Storage Disease Treatment Market Analysis at a glance
Market size, 2025$186.0 Mn placeholder estimate
Forecast, 2034$384.4 Mn placeholder estimate
Growth (CAGR), 2025–20348.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDisease, treatment and end user (see all)
Key playersSanofi, Takeda Pharmaceutical Company Ltd, BioMarin, Amicus Therapeutics, Chiesi (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Lysosomal Storage Disease Treatment Market Analysis Executive Summary

Lysosomal storage disease treatments help people with rare inherited conditions where cells cannot break down certain substances.

Key segments of the lysosomal Storage Disease Treatment market include disease (Gaucher, Fabry and Pompe) and treatment (Enzyme Replacement, Substrate Reduction and Gene Therapy).

Bar chart: Australia Lysosomal Storage Disease Treatment market size, 2024–2034, placeholder estimates. $171.6 Mn in 2024, $186.0 Mn in 2025 and $384.4 Mn in 2034, 8.4% CAGR.
Australia Lysosomal Storage Disease Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Lysosomal Storage Disease Treatment Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the lysosomal Storage Disease Treatment market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the lysosomal Storage Disease Treatment market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the lysosomal Storage Disease Treatment market.

Competitive Landscape for Lysosomal Storage Disease Treatment Market in Australia

The lysosomal Storage Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Lysosomal Storage Disease Treatment Market in Australia

Lysosomal Storage Disease Treatment in Australia: rules and payment

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lysosomal Storage Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Lysosomal Storage Disease Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Lysosomal Storage Disease Treatment in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Lysosomal Storage Disease Treatment market in Australia?
Placeholder estimate: about $186.0 Mn in 2025, rising to about $384.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Lysosomal Storage Disease Treatment market in Australia growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Lysosomal Storage Disease Treatment market report cover?
The report splits the market by disease (Gaucher, Fabry, Pompe, MPS and more), treatment (Enzyme Replacement, Substrate Reduction, Gene Therapy, Chaperone Therapy) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Lysosomal Storage Disease Treatment market?
Key players include Sanofi, Takeda Pharmaceutical Company Ltd, BioMarin, Amicus Therapeutics and Chiesi.
What is driving the Lysosomal Storage Disease Treatment market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the lysosomal Storage Disease Treatment market. More countries now have national rare disease plans.
Who regulates Lysosomal Storage Disease Treatment in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How much research is published on Lysosomal Storage Disease Treatment?
PubMed lists 534 papers on Lysosomal Storage Disease Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on rare diseases and genomics

See the topic